![netFormulary](images/nf_003.gif) |
![NHS](images/NHS3.jpg) |
North East and North Cumbria
ICS Formulary |
Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
08.01 |
Cytotoxic drugs
(1,0)
|
|
![](images/sublink.gif)
Side-effects of cytotoxic drugs (0,0)
|
|
![](images/sublink.gif)
Drugs for cytotoxic-induced side-effects
(4,0)
|
08.01.01 |
Alkylating drugs
(12,1)
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(9,0)
|
08.01.03 |
Antimetabolites
(18,0)
|
08.01.04 |
Vinca alkaloids and etoposide
(5,0)
|
08.01.05 |
Other antineoplastic drugs
(62,2)
|
|
![](images/sublink.gif)
Amsacrine
(1,0)
|
|
![](images/sublink.gif)
CDK inhibitors (0,0)
|
|
![](images/sublink.gif)
Arsenic trioxide
(1,0)
|
|
![](images/sublink.gif)
Bevacizumab
(1,0)
|
|
![](images/sublink.gif)
Bexarotene
(1,0)
|
|
![](images/sublink.gif)
Bortezomib
(1,0)
|
|
![](images/sublink.gif)
Brentuximab vedotin
(1,0)
|
|
![](images/sublink.gif)
Cetuximab
(1,0)
|
|
![](images/sublink.gif)
Dacarbazine and Temozolomide
(2,0)
|
|
![](images/sublink.gif)
Erlotinib
(1,0)
|
|
![](images/sublink.gif)
Hydroxycarbamide
(1,0)
|
|
![](images/sublink.gif)
Imatinab (0,0)
|
|
![](images/sublink.gif)
Ipilimumab
(1,0)
|
|
![](images/sublink.gif)
Mitotane
(1,0)
|
|
![](images/sublink.gif)
Panitumumab
(1,0)
|
|
![](images/sublink.gif)
Pentostatin
(1,0)
|
|
![](images/sublink.gif)
Platinum compounds
(3,0)
|
|
![](images/sublink.gif)
Porfimer sodium and temoporfin
(1,0)
|
|
![](images/sublink.gif)
Procarbazine
(1,0)
|
|
![](images/sublink.gif)
Protein kinase inhibitors
(31,0)
|
|
![](images/sublink.gif)
Taxanes
(4,0)
|
|
![](images/sublink.gif)
Topoisomerase I inhibitors
(2,0)
|
|
![](images/sublink.gif)
Trabectedin
(1,0)
|
|
![](images/sublink.gif)
Trastuzumab
(3,0)
|
|
![](images/sublink.gif)
Tretinoin
(1,0)
|
|
![](images/sublink.gif)
Vismodegib (0,0)
|
08.02 |
Drugs affecting the immune response
(2,0)
|
|
![](images/sublink.gif)
Immunosuppressant therapy (0,0)
|
08.02.01 |
Antiproliferative immunosuppressants
(3,0)
|
08.02.02 |
Corticosteroids and other immunosuppressants
(9,1)
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(6,0)
|
08.02.04 |
Other immunomodulating drugs
(6,0)
|
|
![](images/sublink.gif)
Interferon Alfa
(3,0)
|
|
![](images/sublink.gif)
Interferon beta
(5,0)
|
|
![](images/sublink.gif)
Interferon gamma (0,0)
|
|
![](images/sublink.gif)
Aldesleukin (0,0)
|
|
![](images/sublink.gif)
BCG bladder instillation
(1,0)
|
|
![](images/sublink.gif)
Canakinumab (0,0)
|
|
![](images/sublink.gif)
Dimethyl fumarate
(1,0)
|
|
![](images/sublink.gif)
Fingolimod
(1,0)
|
|
![](images/sublink.gif)
Glatiramer acetate
(1,0)
|
|
![](images/sublink.gif)
Histamine (0,0)
|
|
![](images/sublink.gif)
Lenalidomide, pomalidomide, and thalidomide
(3,0)
|
|
![](images/sublink.gif)
Mifamurtide
(1,0)
|
|
![](images/sublink.gif)
Natalizumab
(1,0)
|
|
![](images/sublink.gif)
Teriflunomide
(1,0)
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
08.03.01 |
Oestrogens
(1,0)
|
08.03.02 |
Progestogens
(3,0)
|
08.03.03 |
Androgens (0,0)
|
08.03.04 |
Hormone antagonists (0,0)
|
08.03.04.01 |
Breast cancer
(10,0)
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(1,0)
|
|
![](images/sublink.gif)
Gonadorelin analogues
(5,0)
|
|
![](images/sublink.gif)
Anti-androgens
(7,0)
|
|
![](images/sublink.gif)
Radiopharmaceuticals (0,0)
|
08.03.04.03 |
Somatostatin analogues
(3,0)
|
|
|
|